scholarly journals Ethical Problems with the Preimplantation Genetic Diagnosis of Human Embryos

2018 ◽  
Vol 24 (1) ◽  
pp. 75-83
Author(s):  
José Tomás Alvarado Marambio ◽  
Manuel J. Santos Alcántara
1998 ◽  
Vol 13 (10) ◽  
pp. 2880-2883 ◽  
Author(s):  
J. C.M. Dumoulin ◽  
M. Bras ◽  
E. Coonen ◽  
J. Dreesen ◽  
J. P.M. Geraedts ◽  
...  

2009 ◽  
Vol 2 (1) ◽  
pp. 3 ◽  
Author(s):  
Anna Mantzouratou ◽  
Anastasia Mania ◽  
Marianna Apergi ◽  
Sarah Laver ◽  
Paul Serhal ◽  
...  

2007 ◽  
Vol 56 (4) ◽  
Author(s):  
Jacques Suaudeau

La diagnosi genetica pre-impiantatoria (Preimplantation genetic diagnosis o PGD) è una tecnica nella quale gli embrioni umani prodotti in vitro per realizzare le tecniche di fecondazione artificiale, vengono selezionati, dal punto di vista genetico, tramite lo studio di uno o di due blastomeri prelevati con una biopsia. Dai reports relativi all’uso della PGD emergono tre punti critici: il primo riguarda le conseguenze della biopsia sullo sviluppo dell’embrione; il secondo la notevole perdita di embrioni nel processo; il terzo l’esattezza diagnostica, con la presenza di falsi positivi e falsi negativi. Oltre al fatto che la PGD è legata alle tecniche di fecondazione artificiale, e, in particolare, alla ICSI, da un punto di vista etico l’obiezione di fondo è che tale pratica si basa su una scarsa considerazione del valore dell’embrione umano. L’aumento della pratica della PGD e l’estensione delle sue indicazioni a casi sempre meno gravi e meno giustificabili dal punto di vista medico è preoccupante. ---------- Preimplantation genetic diagnosis (PGD) is a technique in which early human embryos, obtained in vitro to realize artificial fertilization techniques, are genetically screened for selection, through the study of one or two blastomeres taken by biopsy. Reports on the use of PGD in the world make clear that there are three critical points in it: first regards with consequences of biopsy on developing embryo; second in consideration of the important loss of human embryos in the screening process; third related to inaccuracy of diagnosis, with the presence of false positives and false negatives. Besides the fact that PGD is relate to artificial reproductive techniques, generally to ICSI, the basic ethical objection is based on an undervaluation of the value of human embryos. From a medical point of view the increasing use of PGD and the extension of its indications to cases always more futile and less justified is preoccupying.


Author(s):  
Е.В. Соловьёва ◽  
Л.П. Назаренко ◽  
Л.И. Минайчева ◽  
А.В. Светлаков

Преимплантационная генетическая диагностика (тестирование) (ПГД/ПГТ) моногенных заболеваний направлена преимущественно на предотвращение рождения ребенка с наследственным заболеванием посредством обследования эмбрионов до имплантации в лечебном цикле ЭКО (экстракорпорального оплодотворения). Строгим показанием для ПГД генной болезни служит высокий риск рождения ребенка с тяжелой формой многогенного заболевания при отсутствии противопоказаний и ограничений. С расширением показаний для ПГД и возможностей генетического тестирования возникают вопросы по нормативному регулированию и этической ответственности врача при проведении процедуры. Этические вопросы возникают, когда генетический риск ниже показателя, расцениваемого как высокий, заболевание не может быть однозначно отнесено к тяжелым, а также при рассмотрении возможности переноса аномального эмбриона. Этические аспекты ПГД рассмотрены с точки зрения базовых этических принципов: пользы и непричинения вреда, автономии, справедливости. В сравнении с пренатальной диагностикой, реализация этих принципов при ПГД сталкивается с рядом дополнительных сложных вопросов. Ценность эмбрионов человека, вероятность оставить супружескую пару без детей должны соотноситься с действительным риском и тяжестью возможного заболевания. Preimplantation genetic diagnosis/testing (PGD/PGT) for monogenic disorders is directed on prevention of the birth of the child with a hereditary disorders by means of testing embryos before implantation in IVF (in vitro fertilization). The high risk of severe form of a single gene disease is a strict medical indication for PGD for monogenic disorders at condition of contraindications and restrictions lack. Extension of PGD indications and genetic testing opportunities raises questions on standard regulation and ethical responsibility. Ethical questions are happening if a genetic risk is lower than the «high» or the disease cannot be classified as serious and if abnormal embryo transfer is proposed. Ethical aspects of PGD are considered in terms of basic ethical principles: beneficence, non-maleficence, autonomy and justice. In comparison with prenatal diagnostics, realization of these principles at PGD faces a number of additional difficult questions. The value of the human embryos and probability to have no children has to correspond to the valid risk and severity of a possible disease.


2014 ◽  
Vol 155 (35) ◽  
pp. 1375-1382
Author(s):  
Tamás Kőrösi ◽  
Olga Török ◽  
Gábor Vajta

Recent advancement in both human embryology and genomics has created a completely new situation for practical and widespread application of preimplantation genetic diagnosis and screening with a dramatic effect on assisted reproduction. The mapping of the first human genome and the advancement in sequencing technology and bioinformatics has led to the discovery of the exact genetic background of exponentially increasing number of diseases. In parallel, methods for culturing human embryos have also radically improved, enabling the late transfer, and the procedure of vitrification the safe cryopreservation. In consequence, refined genetic analyses have become available from blastocyst biopsy followed by the application of novel genomic methods. Furthermore, some studies suggest that by the selection of aneuploid embryos the pregnancy- and birth-rates can be increased. The amount and the depth of information obtainable from the embryos raise several technical and ethical questions that can be answered by further prospective randomized trials. Orv. Hetil., 2014, 155(35), 1375–1382.


2016 ◽  
Vol 2016 ◽  
pp. 1-10 ◽  
Author(s):  
Danilo Cimadomo ◽  
Antonio Capalbo ◽  
Filippo Maria Ubaldi ◽  
Catello Scarica ◽  
Antonio Palagiano ◽  
...  

Preimplantation Genetic Diagnosis and Screening (PGD/PGS) for monogenic diseases and/or numerical/structural chromosomal abnormalities is a tool for embryo testing aimed at identifying nonaffected and/or euploid embryos in a cohort produced during an IVF cycle. A critical aspect of this technology is the potential detrimental effect that the biopsy itself can have upon the embryo. Different embryo biopsy strategies have been proposed. Cleavage stage blastomere biopsy still represents the most commonly used method in Europe nowadays, although this approach has been shown to have a negative impact on embryo viability and implantation potential. Polar body biopsy has been proposed as an alternative to embryo biopsy especially for aneuploidy testing. However, to date no sufficiently powered study has clarified the impact of this procedure on embryo reproductive competence. Blastocyst stage biopsy represents nowadays the safest approach not to impact embryo implantation potential. For this reason, as well as for the evidences of a higher consistency of the molecular analysis when performed on trophectoderm cells, blastocyst biopsy implementation is gradually increasing worldwide. The aim of this review is to present the evidences published to date on the impact of the biopsy at different stages of preimplantation development upon human embryos reproductive potential.


Sign in / Sign up

Export Citation Format

Share Document